"*" indicates required fields
This questionnaire is the first step of the Delphi consensus. The goal specifically is to gather your current perspective and experiences using chimeric antigen receptor T-cell (CAR-T) therapy and/or bispecific antibodies (BsAb) for treating relapsed-refactory multiple myeloma (RRMM) in adults in an outpatient setting. The questions focus on the hospital set up required for administration of CAR-T and BsAb in an outpatient setting, the ideal patient profile, as well as the product risk profile for outpatient administration. We also seek to understand your opinion on the risks and benefits of providing these treatments in an outpatient setting.
This questionnaire includes three main sections: an initial section to confirm your eligibility, followed by sections focused on BsAb and CAR-T therapies. Depending on your clinical experience, you may be asked to complete one or both of the latter sections. The questionnaire consists of a total of 52 questions and is expected to take approximately one hour to complete. Please respond based on your professional opinion and experience.
Your valuable input in this round will serve as the foundation for developing the statements that we will seek your consensus on in the next round.